Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ALEC 
Alector Inc (ALEC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ALEC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.83
1 Year Target Price $3.83
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.93% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 299.59M USD | Price to earnings Ratio - | 1Y Target Price 3.83 |
Price to earnings Ratio - | 1Y Target Price 3.83 | ||
Volume (30-day avg) 9 | Beta 1 | 52 Weeks Range 0.87 - 6.37 | Updated Date 09/17/2025 |
52 Weeks Range 0.87 - 6.37 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -142.1% | Operating Margin (TTM) -433.55% |
Management Effectiveness
Return on Assets (TTM) -17.84% | Return on Equity (TTM) -103.99% |
Valuation
Trailing PE - | Forward PE 526.32 | Enterprise Value 11549028 | Price to Sales(TTM) 3.69 |
Enterprise Value 11549028 | Price to Sales(TTM) 3.69 | ||
Enterprise Value to Revenue 0.39 | Enterprise Value to EBITDA -8.4 | Shares Outstanding 101212000 | Shares Floating 84573022 |
Shares Outstanding 101212000 | Shares Floating 84573022 | ||
Percent Insiders 10.37 | Percent Institutions 77.09 |
Upturn AI SWOT
Alector Inc
Company Overview
History and Background
Alector Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. Founded in 2013, it aims to harness the power of the immune system to combat diseases like Alzheimer's and Parkinson's. Significant milestones include developing proprietary antibody platforms and advancing several drug candidates into clinical trials. It has partnered with major pharmaceutical companies like AbbVie and GSK.
Core Business Areas
- Immuno-Neurology Drug Development: Alector focuses on developing therapeutics that modulate the immune system to treat neurodegenerative diseases.
Leadership and Structure
Alector is led by a management team with experience in immunology and neuroscience. The organizational structure is comprised of research, development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- AL001 (GSK3372685): A monoclonal antibody targeting SIGLEC3 (CD33) to enhance microglial function in Alzheimer's disease. Phase 3 trial is ongoing. There is no current market share. Competitors include other Alzheimer's drug developers like Biogen (ADUHELM) and Eisai (LEQEMBI).
- AL101: A progranulin (PGRN) boosting antibody for frontotemporal dementia (FTD) with GRN mutations. Phase 3 trial is ongoing. There is no current market share. Competitors include other FTD drug developers, however AL101 is a first-in-class therapeutic.
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing, with a significant unmet need for effective therapies. Major players are investing heavily in research and development. The market is characterized by high regulatory hurdles and long development timelines.
Positioning
Alector is positioned as a pioneer in immuno-neurology, focusing on novel targets within the immune system to treat neurodegenerative diseases. Its competitive advantage lies in its proprietary antibody platforms and strategic partnerships.
Total Addressable Market (TAM)
The TAM for neurodegenerative disease therapies is estimated to be over $50 billion. Alector is positioned to capture a significant share of this market with successful development and commercialization of its drug candidates.
Upturn SWOT Analysis
Strengths
- Pioneering immuno-neurology approach
- Strong proprietary antibody platforms
- Strategic partnerships with major pharmaceutical companies
- Diverse pipeline of drug candidates
- Experienced management team
Weaknesses
- High risk of clinical trial failure
- Dependence on partnerships for funding
- Limited commercial infrastructure
- Cash burn
- No approved product to generate revenue
Opportunities
- Expanding into new neurodegenerative disease areas
- Acquiring complementary technologies or companies
- Securing regulatory approvals for key drug candidates
- Expanding partnerships with other pharmaceutical companies
- Capitalizing on the aging population and increasing prevalence of neurodegenerative diseases
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- BIIB
- ESAI
- LLY
Competitive Landscape
Alector faces competition from established pharmaceutical companies with greater resources and broader portfolios. However, Alector's focus on immuno-neurology provides a differentiated approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of drug candidates through clinical trials and the formation of strategic partnerships.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of drug candidates. Analyst estimates vary widely depending on these factors.
Recent Initiatives: Recent initiatives include advancing AL001 and AL101 into late-stage clinical trials, expanding partnerships, and exploring new immuno-neurology targets.
Summary
Alector is a high-risk, high-reward biotechnology company pioneering immuno-neurology. Its strength lies in its novel therapeutic approach and strategic partnerships. The company's future hinges on the success of its clinical trials, particularly for AL001 and AL101. Alector must manage its cash burn rate and secure regulatory approvals to realize its potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Press Releases
- Analyst Reports
- Industry News Sources
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alector Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-02-07 | Co-Founder, CEO & Director Dr. Arnon Rosenthal Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 163 | Website https://www.alector.com |
Full time employees 163 | Website https://www.alector.com | ||
Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial. It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, the company's preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.